• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Opportunities in Human Embryonic Stem Cell (hESC) Products - Trends and Forecasts to 2017 - Product Image

Opportunities in Human Embryonic Stem Cell (hESC) Products - Trends and Forecasts to 2017

  • ID: 2615838
  • October 2013
  • Region: Global
  • 158 Pages
  • BioInformant

FEATURED COMPANIES

  • BD Biosciences
  • Cellartis AB
  • Chemicon
  • Geron
  • Invitrogen
  • Novocell
  • MORE

Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into any mature cell type. Categorized by stage of life, several broad categories of stem cells exist, including:

- Embryonic stem cells, derived from blastocysts
- Post-natal stem cells, derived from newborn tissues
- Adult stem cells, found in adult tissues – including hematopoietic stem cells, mesenchymal stem cells, neural stem cells, and more
- Induced pluripotent stem cells, reprogrammed from adult cells
- Cancer stem cells, which give rise to clonal populations of cells that form tumors or disperse in the body

Embryonic stem cells are stem cells derived from the inner cell mass of a blastocyst, which is a stage reached four to five days post-fertilization. They are the most pluripotent of all stem cell types and can develop into over 200 different cell types of the human body. Human embryonic stem cells (hESCs) were first derived from mouse embryos in 1981 by Martin Evans and Matthew Kaufman, and independently by Gail R. Martin. In 1995, the first successful culturing of embryonic stem cells from non-human READ MORE >

FEATURED COMPANIES

  • BD Biosciences
  • Cellartis AB
  • Chemicon
  • Geron
  • Invitrogen
  • Novocell
  • MORE

I. STRATEGIC OVERVIEW

II. ACCESS & AVAILABILITY OF hESC LINES
A. NIH Registry Approved hESC Lines
B. Sources of Additional Published hESC Lines
C. Sources of Additional Unpublished hESC Lines

III. END-USER APPLICATIONS OF hESCs
A. Basic Research
B. Cellular Therapies
1. Overview
2. Characterization of Source hESCs for Cellular Therapy
3. Promising Areas of hESC Cellular Therapy Research
a. Heart Regeneration
b. Pancreatic Islet Cell Replacement
c. Neural Regeneration
C. Tissue Engineering
D. Toxicology Testing
1. High-Value Opportunities
2. Optimization & Validation of hESC Toxicology Assays

IV. PATENT ENVIRONMENT
A. Landmark hESC Patents: WARF “Composition of Matter” Patents
1. Background
2. Licensing of WARF Patent Rights
3. WARF Patent Exemption: Federal Rights to hESC Research
4. U.S. WARF Patent Challenges
5. Circumventing WARF Patent Rights Using Geographic Limitations
B. Global Stem Cell Patent Landscape
C. U.S. Patents of Importance
1. Geron Corporation Patents
2. Regents of the University of California Patents
3. BresaGen, Inc. Patents
4. Regeneron Pharmaceuticals, Inc.
5. Vanderbuilt University Patents
D. Worldwide Patents of Importance
1. ES Cell International PTE Ltd. Patents (Singapore)
2. DNAVEC Research Inc. Patents (Japan)
3. University of Edinburgh Patents (Scotland)
E. Summary of the hESC Intellectual Property Landscape

V. MARKET TREND ANALYSIS - FUTURE GROWTH PROJECTIONS
A. Scientific Publication Analysis
1. Historical Analysis (Trailing 10 Years)
2. Future Growth Predictions (5-Year Forecasts, 2013-17)
3. Breakdown of ESC Research by Species
B. Grant Analysis
C. Patent Analysis

VI. MARKET SIZE
A. Definitions
B. Experimental Approach
C. Annual Market Size - Human Embryonic Stem Cell Products

VII. MARKET CHARACTERIZATION
A. Key Research Applications
1. Size of Market Segments
2. Trend Data
B. Geographical Breakdown (Country-by-Country Breakdown)

VIII. hESC RESEARCH SUPPLY COMPETITORS
A. Cellartis AB
B. Vitrolife
C. Tataa Biocenter
D. Invitrogen
E. Stem Cell Technologies
F. BD Biosciences
G. Chemicon
H. R&D Systems
I. SA Biosciences
J. Thermo Scientific
K. Australian Stem Cell Centre

IX. SPECIALTY PHARMACEUTICAL COMPANIES DEVELOPING hESC THERAPIES
A. Geron
B. Novocell
C. Cell Cure Neurosciences Ltd
D. Cell Dynamics International
E. Advanced Cell Technology

X. TOXICOLOGY TESTING LEGISLATION
A. European Union Ban of Animal-Testing for Cosmetic Development (2013)
B. Responses to the European Ban on Animal Testing for Cosmetic Development
1. Overview
2. Skin Irritation
3. Eye Irritation
4. Skin Sensitisation
5. Mutagenicity/Genotoxicity
6. Reproductive Toxicity
C. EU Legislation Regarding Animal-Based Testing for Drug Discovery

XI. STRATEGIC PRODUCT & TECHNOLOGY DEVELOPMENT
A. Product Categories
B. Product Ideas & Suggestions
1. Areas of Underdeveloped Competition
2. Mouse ESC Products
3. iPS Cells Products
4. Non-animal-derived Culture Reagents for hESCs
5. Strategic Collaborations
6. Products for Generating Pure ESC populations
7. hESC Toxicity Assay Kit

XII. STRATEGIES FOR ACCESSING THE MARKETPLACE
A. Top Research Institutions Performing hESC Research
1. Academic Labs
2. Private Labs
3. Government Labs
4. International Labs
B. Events of Interest - hESC Conferences & Symposiums

XIII. SCIENTIST PANEL: DETAILED END-USER SURVEY
A. Survey Overview
B. Characterization of Market Survey Respondents
1. Geographic Distribution of Respondents
2. Respondent Breakdown by Industry Affiliation
3. Breakdown of Respondents by Duration of iPSC Research Activity
C. Survey Findings
1. General Scope
2. Comparison of Providers / Brand Preferences
3. Marketing Assessment
D. Terms Used in Online Product Search

XIV. CONCLUSIONS

APPENDIX

Human Embryonic Stem Cell Research Centers & Contact Information

- Australian Stem Cell Centre
- BD Biosciences
- Cellartis AB
- Chemicon
- Geron
- Invitrogen
- Novocell
- R&D Systems
- SA Biosciences
- Tataa Biocenter
- Thermo Scientific
- Vitrolife

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos